🇺🇸

US SEC Filing Intelligence

· daily

Biotech Small-Cap Approvals — August 14, 2026

The August 14, 2026 approval digest is dominated by 8 generic/biosimilar approvals, with zero NMEs, zero label expansions, and zero biosimilars (as defined by the data provider, though all are categorized as 'FALLBACK' type). The period lacks any high-value first-in-class or breakthrough therapy catalysts, resulting in a uniformly neutral signal across all events. The dominant theme is the continued commoditization of established small-molecule and contrast-agent markets, with Aurobindo Pharma receiving three approvals (triamcinolone acetonide, brivaracetam, vancomycin hydrochloride) and Lupin, Novitium Pharma, Huaren Pharmaceutical, Viwit Pharm, and Macleods Pharma each receiving one. The highest-conviction signal is the absence of any NME or priority review approval, which suggests a quiet period for small-cap biotech catalysts and reinforces a defensive, non-event-driven stance for the sector. The key risk is the lack of commercial differentiation among these approvals, offering limited pricing power and no new therapeutic options for investors to underwrite.

8 total filings
· daily

Significant Contract Modifications ($10M+) — August 14, 2026

The three contracts analyzed total $338.1 million in obligations, all from civilian agencies (0% defense-related), with the Department of Homeland Security (DHS) dominating via a $215.5 million award to Eastern Air Express LLC for ICE operational support. The highest-conviction signal is Oracle Health Government Services' $114.4 million VA EHRM contract, which offers stable multi-year revenue through 2027. Key risk: Eastern Air Express's sole-source, non-competed award raises pricing and protest vulnerability concerns, while Lockheed Martin's $8.2 million Coast Guard task order is immaterial for the defense prime. Overall, the digest highlights civilian agency IT and operational spending stability, but with limited competitive validation and no defense exposure.

3 total filings
· daily

New Drug Approvals (Original) — August 14, 2026

The August 14, 2026 FDA approval stream is entirely composed of 8 biosimilar (FALLBACK) approvals, with zero NMEs, zero label expansions, and zero Breakthrough or Priority Review designations. This period reflects a pure generics/biosimilar wave, dominated by established molecules such as FOSFOMYCIN TROMETHAMINE (NOVITIUM PHARMA), VALSARTAN (HUAREN PHARMACEUTICAL CO LTD), and BRIVARACETAM (AUROBINDO PHARMA). The highest-conviction signal is AUROBINDO PHARMA’s three separate biosimilar approvals (TRIAMCINOLONE ACETONIDE, BRIVARACETAM, VANCOMYCIN HYDROCHLORIDE), signaling strong execution capability in the generics space. The key risk is the absence of any novel therapeutic innovation, which may disappoint investors seeking high-growth NME catalysts, and the potential for accelerated price erosion in already crowded markets like valsartan and vancomycin.

8 total filings
· daily

Contract Deobligations Alert — August 14, 2026

The three contracts analyzed total $338.1 million in obligations, all from civilian agencies (0% defense), with the Department of Homeland Security (DHS) as the dominant spender across two awards. The highest-conviction signal is Oracle Health Government Services' $114.4 million sole-source VA EHRM contract, a multi-year bullish indicator for federal IT modernization. However, the largest award—$215.5 million to Eastern Air Express LLC for ICE operational support—carries execution risk due to its non-competitive, firm-fixed-price structure and reliance on option exercises. Key risk: the non-competitive nature of both the Eastern Air Express and Oracle awards limits market validation and raises protest vulnerability.

3 total filings
· daily

Contract Option Exercises — August 14, 2026

This digest covers $338.1 million in total obligations across three civilian agency contract actions announced in August 2026, with zero defense-related awards. The dominant theme is Department of Homeland Security (DHS) spending on aviation support and critical infrastructure IT maintenance, led by a $215.5 million sole-source award to Eastern Air Express LLC for ICE aircraft operations—a material revenue stream for a small, disadvantaged business. The highest-conviction signal is Oracle Health Government Services’ $114.4 million non-competed VA EHRM support contract, which provides multi-year revenue stability for Oracle in a priority IT modernization area through 2027. Key risks include the lack of competitive validation on two of three awards and fixed-price margin pressure on Eastern Air Express. Investors should watch option exercises on Eastern Air Express’s contract as a catalyst for further revenue visibility.

3 total filings
· daily

Federal IT & Cybersecurity Contracts — August 14, 2026

This digest covers a single, high-value civilian contract: a $114.35 million firm-fixed-price delivery order from the Department of Veterans Affairs to Oracle Health Government Services, Inc. for its EHRM Forward Deployed Solution Set. The contract is entirely civilian, with no defense exposure, and underscores the VA's ongoing IT modernization push. The highest-conviction signal is Oracle's multi-year revenue visibility through 2027, though the non-competitive award structure introduces execution and protest risk. Key watch items include option exercises and potential legal challenges to the sole-source nature of the award.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — August 14, 2026

The two contracts analyzed total $329.9 million in obligations, with zero defense-related awards, underscoring a purely civilian procurement focus. The dominant theme is DHS/ICE operational support via a $215.5 million sole-source award to Eastern Air Express LLC, which carries medium pricing risk and limited competitive validation. The second contract is a $114.4 million multi-year VA IT award to Oracle Health Government Services, providing stable revenue visibility through 2027 but with non-competitive dynamics. The highest-conviction signal is Oracle's bullish, low-risk VA contract, while the key risk is Eastern Air Express's sole-source structure and potential for protest or margin pressure under firm-fixed-price terms.

2 total filings
· daily

General Federal Contracts — August 14, 2026

The three contracts total $338.1 million in obligations, all from civilian agencies (DHS/ICE, VA, and USCG), with zero defense-related awards, underscoring a civilian-led procurement theme. The dominant sector is government services and IT modernization, led by a $215.5 million ICE air transport contract to Eastern Air Express and a $114.4 million VA EHRM delivery order to Oracle Health. The highest-conviction signal is Oracle's multi-year, non-competed VA contract, which provides stable revenue visibility through 2027 and aligns with federal IT modernization priorities. Key risks include the non-competitive nature of two of the three awards (Eastern Air Express and Oracle), which raises pricing and protest concerns, and the relatively small Lockheed Martin task order that is immaterial to its overall revenue. Watch for option exercises on the Eastern Air Express contract (potential $327.9 million total) and any protests on the Oracle award, as these could impact revenue certainty.

3 total filings
· daily

S&P 500 Technology Sector SEC Filings — August 14, 2026

The S&P 500 Technology sector is exhibiting a pronounced insider selling pattern, with three major companies—KLA Corp, Arista Networks, and CrowdStrike—reporting significant executive stock sales, all executed under Rule 10b5-1 plans. Total insider sales exceeded $60 million in the reporting period, with Arista's CEO alone selling approximately $47.2 million. These sales, while pre-planned, may signal a peak valuation sentiment among top executives, especially given the sector's recent run-up. Meanwhile, AppLovin's director exercised and gifted shares, indicating a non-cash event with neutral market implications. IBM's 8-K filing was purely procedural with no material business developments, and the 13F-HR filings from NVIDIA and AMD provided no actionable data due to their nature as institutional holdings reports. The overarching theme is one of caution, as insider selling volume and value are elevated, suggesting that management teams may be taking profits at current levels. No positive period-over-period trends or guidance changes were reported, reinforcing a neutral-to-bearish short-term outlook for the sector.

4 high priority 3 medium 7 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — August 14, 2026

The August 14, 2026 batch of 50 filings reveals a dominant theme of passive institutional repositioning with notable activist stirrings. A key portfolio-level trend is the widespread reduction in stakes by major passive investors like BlackRock and Vanguard, with several positions decreasing by 90-130 basis points, indicating broad index rebalancing or sector rotation rather than company-specific distress. The most critical development is Fidelity's complete exit from Tango Therapeutics, a high-materiality signal that could trigger further selling. Conversely, an activist 13D filing at INNOVATE Corp. introduces a catalyst for potential value creation. Insider activity is limited, but the presence of healthcare-focused specialists like RA Capital and Perceptive Advisors holding significant passive stakes (5.7%-12.4%) in biotech suggests selective institutional conviction. The period-over-period data highlights a clear pattern of passive holders trimming positions, while a few specialized funds maintain or increase their focus, creating a bifurcated landscape of risk and opportunity.

1 high priority 49 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — August 14, 2026

The S&P 500 Financials sector digest for August 14, 2026, reveals a market dominated by passive institutional positioning and capital return events, with limited aggressive directional signals. The five major 13F filings from Bank of America ($1.55T), Wells Fargo ($617B), Charles Schwab ($751B), T. Rowe Price ($152.6B), and Goldman Sachs show a combined $3.07 trillion in disclosed equity holdings, heavily skewed toward mega-cap technology and healthcare, indicating a consensus defensive rotation. Insider activity is notably bearish, with two significant sales: a PNC executive sold $858K worth of stock, and Aflac's largest shareholder, Japan Post, sold shares under a 10b5-1 plan, suggesting pre-planned portfolio rebalancing rather than operational concern. Capital allocation is active in the private credit space, with JPMorgan launching a $1.96B tender offer to repurchase 5% of net assets, a strong signal of confidence in NAV and liquidity management. The absence of earnings guidance or forward-looking statements across all filings points to a quiet period post-Q2 earnings, making the scheduled events and tender offer deadlines the primary near-term catalysts. Overall, the digest suggests a sector that is well-capitalized and stable, but with insider selling and a lack of bullish conviction from management teams, warranting a cautious, event-driven approach.

4 high priority 11 medium 15 total filings
· daily

S&P 500 Energy Sector SEC Filings — August 14, 2026

The S&P 500 Energy sector shows contrasting insider signals on August 14, 2026, with Marathon Petroleum's VP of Refining executing a significant $2.05M stock sale, indicating potential bearish sentiment from operational leadership, while Texas Pacific Land Corp sees a nominal insider purchase from a major holder, suggesting stability. No period-over-period comparisons, forward-looking guidance, capital allocation data, or operational metrics were available in the filings, limiting trend analysis. The material insider sale at Marathon Petroleum, representing over 35% of the executive's known holdings, warrants close monitoring for further insider activity and potential earnings headwinds. The sector theme centers on divergent insider behavior, with one company showing confidence and another signaling caution, which could reflect broader uncertainty in refining margins versus land asset valuations.

2 high priority 2 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — August 14, 2026

On August 14, 2026, Target Corp filed an 8-K disclosing entry into and termination of material definitive agreements and creation of a direct financial obligation, but provided no specific financial terms, transaction values, or strategic details. The filing is categorized as neutral sentiment with medium risk and a materiality score of 5/10, reflecting significant uncertainty due to the lack of quantitative data. With only one filing in scope for the Consumer Staples stream, no multi-company trends or sector-wide patterns can be established. The absence of enriched data fields—such as period-over-period comparisons, insider trades, forward-looking guidance, capital allocation actions, or operational metrics—severely limits the depth of actionable insights. Investors should view this filing as a placeholder for undisclosed material events, warranting close monitoring for subsequent SEC filings or press releases that may clarify financial impact or strategic rationale.

1 high priority 1 total filings
· daily

S&P 500 Industrials Sector SEC Filings — August 14, 2026

The four filings in this digest reveal a mix of capital market activity, insider buying, and passive institutional positioning within the S&P 500 Industrials sector. Caterpillar Financial Services successfully raised $1.35 billion in medium-term notes, indicating robust access to debt capital at attractive rates, which supports its lending capacity for equipment sales. Insider buying at Eaton and Republic Services signals management confidence, with Republic Services' 10% owner making a substantial $33.9M purchase. Berkshire Hathaway's passive 8.7% stake in Delta Air Lines, disclosed via 13G/A, underscores a long-term value investment in the airline sector. No negative trends or guidance changes were flagged, suggesting a stable operating environment. The sector exhibits strong capital deployment through debt issuance and insider accumulation, with no red flags in the current data.

2 high priority 2 medium 4 total filings
· daily

US Material Events SEC 8-K Filings — August 14, 2026

The August 14, 2026 batch of 50 filings reveals a market dominated by capital structure engineering and governance transitions, with a notable absence of broad operational growth trends. The most significant events are two transformative M&A deals—SpaceX's $60B stock acquisition of Anysphere (Cursor) and Skye Bioscience's reverse merger with Redx Pharma—which represent high-conviction, long-duration bets. Capital markets activity is intense, with five companies (Proficient Auto, Delek Logistics, EDAP TMS, Dyadic, Vuzix) raising over $600M combined, signaling a robust appetite for equity and convertible financing, particularly among smaller-cap and pre-revenue firms. However, this is counterbalanced by severe governance red flags: a sudden CFO departure at Beauty Health Co, a material earnings restatement at HCW Biologics, and a massive authorized share increase at Zoomcar, all pointing to underlying instability. Insider trading data is sparse, but the lack of insider buying in these capital raises suggests management is not aggressively signaling confidence. The period-over-period data available from Neumora and Lifeward shows a trend of improving operational efficiency (Neumora cut losses 18% YoY) but margin compression due to tariffs and FX (Lifeward gross margin down 300 bps), a theme likely to persist. The overall picture is one of strategic realignment and capital preservation, with investors needing to differentiate between companies executing disciplined transformations and those engaging in dilutive or opaque financial maneuvers.

50 high priority 50 total filings
· daily

Insider Trading Pulse — August 14, 2026

The August 14, 2026 insider trading digest reveals a market with a clear divergence between strategic buying and routine selling. The most significant signal is a massive $6.04M open-market purchase by Borr Drilling's largest director, Tor Olav Troim, alongside a $502K buy by another director, indicating strong insider conviction in the offshore drilling sector's recovery. This is complemented by a $522K purchase from Matador Resources' Chairman and CEO, reinforcing a bullish theme in energy. However, this optimism is countered by notable insider selling in the financial sector, including an $858K sale by a PNC Financial executive and a $617K sale by China Yuchai's CFO, which nearly liquidated his entire position. The day also featured a wave of routine equity awards at Broadridge Financial Solutions and several beneficial ownership reports for Evanston Multi-Alpha Fund, which are non-actionable. Overall, the data suggests a tactical rotation: insiders are buying beaten-down energy and select tech names while reducing exposure to financials and consumer discretionary stocks like Winnebago, where the CEO sold $394K under a 10b5-1 plan.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — August 14, 2026

The Dow 30 filings for August 14, 2026, reveal a bifurcated landscape: capital markets activity is robust, with Caterpillar Financial Services tapping debt markets for $1.35B and JPMorgan Private Markets Fund executing a 5% tender offer, signaling strong institutional demand for yield and liquidity. However, insider sentiment is sharply negative at Johnson & Johnson, where the CEO sold $26.7M in stock—the largest insider sale in the cohort—while Amazon's complex S-4 merger filing for Globalstar introduces significant execution risk and valuation uncertainty. IBM's 8-K was purely procedural, offering no new insights. The 13F filings from NVIDIA and Goldman Sachs lacked sufficient detail for trend analysis. The overarching theme is one of capital deployment (debt issuance, M&A, buybacks) clashing with insider caution, suggesting a market where corporate confidence is high but management teams are hedging personal exposure.

2 high priority 5 medium 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 14, 2026

On August 14, 2026, seven US public companies filed delisting notices, creating a dramatic cluster of corporate distress signals within a single 24-hour period. All filings are under Item 3.01 (failure to satisfy a continued listing rule or standard), with four (Adagio Medical, REED'S, Optimum Communications, Teads Holding) lacking any specific reason for delisting and no financial or forward-looking guidance, amplifying investor uncertainty. SES AI Corp's partial delisting of only its public warrants (SES WS) due to 'abnormally low selling price' stands out as a nuanced event, while Worksport Ltd and Actinium Pharmaceuticals carry critical-to-high risk designations. The compressed timing and lack of quantified financial impact across all filings suggest a sector-agnostic liquidity or compliance crisis, with the average materiality score of 8.6/10 underscoring portfolio-level risk. No positive period-over-period trends, insider activity, or capital allocation data were available, reinforcing a uniformly bearish and opaque distress environment.

7 high priority 7 total filings
· daily

Global High-Priority Regulatory Events — August 14, 2026

The August 14, 2026, digest reveals a market bifurcated between aggressive corporate restructuring and systemic distress. A dominant theme is the wave of corporate insolvencies in India, with several companies like BIL Vyapar, Bloom Dekor, and Electrotherm reporting deeply negative financials, qualified audit opinions, and ongoing CIRP proceedings, signaling a peak in the credit cycle's stress phase. Concurrently, there is significant M&A and capital allocation activity, highlighted by SpaceX's $60B all-stock acquisition of Cursor and Adani Energy's strategic transmission asset purchase, indicating that well-capitalized entities are deploying capital for long-term growth. A cluster of private credit and interval funds are conducting routine tender offers to provide liquidity, a neutral signal of standard operations. The delisting of Actinium Pharmaceuticals and Reed's Inc. underscores ongoing challenges for small-cap biotech and consumer goods companies in maintaining exchange listings. The most critical development is the sheer volume of insolvency-related filings, which suggests a concentrated risk event in the Indian corporate sector that warrants close monitoring for contagion effects. Portfolio-level patterns show a clear divergence: capital is flowing towards strategic, high-growth acquisitions while being withdrawn from distressed or non-core assets, creating a 'barbell' market environment.

50 high priority 50 total filings